Atrial fibrillation: is there a role for cardiac troponin?

Alireza Sepehri Shamloo; Arash Arya; Angeliki Darma; Sotirios Nedios; Michael Döring; Andreas Bollmann; Nikolaos Dagres; Gerhard Hindricks

doi:10.1515/dx-2019-0072

Atrial fibrillation: is there a role for cardiac troponin?

Diagnosis (Berl). 2020 Jan 9;8(3):295-303. doi: 10.1515/dx-2019-0072. Print 2021 Aug 26.

Authors

Alireza Sepehri Shamloo¹, Arash Arya¹, Angeliki Darma¹, Sotirios Nedios¹, Michael Döring¹, Andreas Bollmann¹, Nikolaos Dagres¹, Gerhard Hindricks¹

Affiliation

¹ Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

PMID: 31913848
DOI: 10.1515/dx-2019-0072

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia, and its prevalence rate is expected to be doubled over the next decades. Despite the wide use of biomarkers in the management of different cardiac diseases such as myocardial infarction and heart failure, utilization of biomarkers in AF management is not routinely recommended by current guidelines. There is also growing evidence that higher levels of cardiac-specific troponin, as an intracellular protein involved in cardiomyocyte contraction, may be associated with the risk of incident and recurrent AF and its complications. In the present paper, we review the association between troponin and AF and propose clinical suggestions for use of troponin in the management of AF patients.

Keywords: atrial fibrillation; biomarker; risk score; troponin.

Publication types

Review